A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

BACKGROUND: The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer (OC) or...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yaxin, Wang, Wei, Yin, Rutie, Zhang, Youzhong, Zhang, Yu, Zhang, Keqiang, Pan, Hongming, Wang, Ke, Lou, Ge, Li, Guiling, Zhang, Ruyan, Li, Kun, Rao, Jing, Zhang, Ben, Wang, Yuting, Wang, Quanren, Gao, Yunong, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542255/
https://www.ncbi.nlm.nih.gov/pubmed/37775744
http://dx.doi.org/10.1186/s12916-023-03046-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542255/
https://www.ncbi.nlm.nih.gov/pubmed/37775744
http://dx.doi.org/10.1186/s12916-023-03046-8

Ejemplares similares